Finance

Lists
Why is 603259 down 6,60%?
Dive Deeper
603259:SHA
WuXi AppTec Co Ltd
144,30 CNY
-6,60%
(-10,20) 1D
16 ოქტ, 15:00:01 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 603259...
Open
156,94 CNY
High
159,92 CNY
Low
139,05 CNY
Mkt. cap
447,48 მლრ.
Avg. vol.
34,02 მლნ.
Volume
83,61 მლნ.
Dividend
1,45%
Quarterly dividend
0,52 CNY
Ex-dividend date
4 სექ. 2026
P/E ratio
19,63
52-wk high
173,60 CNY
52-wk low
87,09 CNY
EPS
7,35 CNY
Shares outstanding
1,05 მლრდ.
No. of employees
36 ათ.
Open
156,94 CNY
High
159,92 CNY
Low
139,05 CNY
Mkt. cap
447,48 მლრ.
Avg. vol.
34,02 მლნ.
Volume
83,61 მლნ.
Dividend
1,45%
Quarterly dividend
0,52 CNY
Ex-dividend date
4 სექ. 2026
P/E ratio
19,63
52-wk high
173,60 CNY
52-wk low
87,09 CNY
EPS
7,35 CNY
Shares outstanding
1,05 მლრდ.
No. of employees
36 ათ.
News stories
From web sources and news partners
Profile
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe. Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
About WuXi AppTec Co Ltd
CEOსტივ იანგ | გე ლი
Employees35,6 ათ.
Founded1 დეკ. 2000
Headquarters-
SectorHealth care
Websitewuxiapptec.com.cn
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
12,04 მლრდ.
10,97 მლრდ.
12,44 მლრდ.
16,46 მლრდ.
Cost of goods sold
6,07 მლრდ.
4,91 მლრდ.
6,17 მლრდ.
-
Cost of revenue
6,07 მლრდ.
4,91 მლრდ.
6,17 მლრდ.
-
Research and development expenses
311,73 მლნ.
236,94 მლნ.
266,96 მლნ.
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
854,49 მლნ.
853,67 მლნ.
891,80 მლნ.
-
Operating expense
1,38 მლრდ.
1,26 მლრდ.
1,22 მლრდ.
-
Total operating expenses
7,45 მლრდ.
6,17 მლრდ.
7,39 მლრდ.
-
Operating income
4,59 მლრდ.
4,80 მლრდ.
5,04 მლრდ.
-
Other non operating income
-470,36 მლნ.
281,37 მლნ.
-266,37 მლნ.
-
EBT including unusual items
5,13 მლრდ.
6,75 მლრდ.
5,61 მლრდ.
-
EBT excluding unusual items
5,11 მლრდ.
6,95 მლრდ.
5,19 მლრდ.
-
Income tax expense
1,55 მლრდ.
1,09 მლრდ.
936,77 მლნ.
-
Effective tax rate
30,19%
16,12%
16,71%
-
Other operating expenses
57,96 მლნ.
25,84 მლნ.
726,05 ათ.
-
Net income
3,51 მლრდ.
7,08 მლრდ.
4,65 მლრდ.
-
Net profit margin
29,18%
64,49%
37,40%
-
Earnings per share
1,24
1,42
1,57
2,20
Interest and investment income
1,21 მლრდ.
1,87 მლრდ.
439,82 მლნ.
-
Interest expense
-226,71 მლნ.
-
-30,95 მლნ.
-
Net interest expenses
981,72 მლნ.
1,87 მლრდ.
408,87 მლნ.
-
Depreciation and amortization charges
-
-
-
-
EBITDA
5,21 მლრდ.
5,61 მლრდ.
5,85 მლრდ.
-
Gain or loss from assets sale
-158,03 მლნ.
218,40 მლნ.
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები